Mesoblast share price rips 12% on financial and operational updates

Mesoblast has set a price for its recently-approved flagship drug, which will go to market over the next few weeks.

| More on:
Doctor doing a telemedicine using laptop at a medical clinic

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mesoblast Ltd (ASX: MSB) share price leapt 11.8% to $2.75 in early trading on Thursday after two announcements from the ASX biotech.

Mesoblast released its 1H FY25 results and announced that pricing had been set for its recently approved flagship drug, remestemcel-L, or Ryoncil, in the United States.

The drug will be made available to US clinics for ordering this quarter.

The Mesoblast share price opened at $2.69, up from $2.46 at yesterday's close. The ASX biotech share is currently trading for $2.67, up 8.33%.

Let's check out the 1H FY25 report.

Mesoblast share price surges on half-yearly results

Here are the highlights of the report:

  • Total revenue of US$3.2 million, down from $3.4 million in 1H FY24
  • Loss after tax of US$47.9 million compared to US$32.5 million for H1 FY24
  • Net Cash Outflow of US$20.7 million, down from US$26.6 million in H1 FY24
  • Cash balance of US$38 million and pro-forma cash of approximately US$200 million

What else happened in 1H FY25?

The biggest event during the half was the approval of Ryoncil to treat the devastating steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children aged two years and older.

The Mesoblast share price skyrocketed by almost 70% between 19 December and 2 January after the company announced approval from the United States Food and Drug Administration (FDA).

Mesoblast shares hit a four-year high of $3.37 per share on 2 January.

SR-aGvHD is a life-threatening condition with a high mortality rate.

Approximately 10,000 patients, including 1,500 children, undergo an allogeneic bone marrow transplant every year in the US.

Approximately one in two patients develop aGvHD, and almost half of them do not respond to the current first-line treatment of steroids.

Mesoblast is now collaborating with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) in the US to conduct a pivotal trial of Ryoncil for adult patients with SR-aGvHD.

Created with Highcharts 11.4.3Mesoblast PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

What did Mesoblast management say?

Dr Silviu Itescu, Chief Executive of Mesoblast, said:

Our FDA approved product Ryoncil will be available in the coming weeks to the children with SRaGvHD in need of life-saving therapy.

The treatment has delivered long-term survival outcomes in these very high-risk patients and we are pleased with the benefits and value that this treatment brings to patients and their healthcare providers at specialized transplant centers across the U.S..

What's next for Mesoblast?

Mesoblast said Ryoncil would become available to clinics over the next few weeks.

The company said the wholesale acquisition cost (WAC) of Ryoncil had been calculated and set at US$194,000 per intravenous infusion.

Ryoncil will be distributed to US treatment centers by cryogenic services provider, Cencora.

In other news, Mesoblast has conducted a pilot study to see whether Ryoncil may be an effective treatment for inflammatory bowel disease, including Crohn's disease.

The study "demonstrated positive outcomes" in adult patients and added to existing Mesoblast data showing Ryoncil can induce early remission in Crohn's disease.

Mesoblast intends to meet with the FDA to discuss another drug, Revascor, to treat chronic heart failure. The FDA has already indicated its support for an accelerated approval pathway.

The company is also enrolling US participants in a confirmatory phase 3 trial of rexlemestrocel-L, which treats chronic lower back pain.

The FDA has approved the design of the trial.

Mesoblast share price snapshot

The Mesoblast share price has risen 768% over the past 12 months.

Should you invest $1,000 in Mesoblast Limited right now?

Before you buy Mesoblast Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Mesoblast Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Bronwyn Allen has positions in Mesoblast. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two doctors wearing white coats look closely at a medical imaging x-ray as the share prices of ASX 200 healthcare shares improve in FY23
Healthcare Shares

Pro Medicus shares climb 33% in less than a month, have I missed the dip?

Pro Medicus shares have soared. Is it the right time to invest?

Read more »

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords share just rocketed 19% on BIG news

Investors are sending this ASX All Ords share flying on Monday. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Healthcare Shares

Why is this ASX All Ords stock surging 14% today?

This stock is starting the week strongly. But why? Let's find out.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

Guess which ASX All Ords stock is rocketing 58% on big US news

What is getting investors excited today? Let's find out.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 reasons to buy this quality ASX 200 healthcare share today

A leading expert expects this outperforming ASX 200 healthcare share will keep running hot.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Brokers tip 4 ASX 200 healthcare shares to buy now

Healthcare is a defensive sector that can provide useful cover for investors when the market is volatile.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

How Trump's tariffs have created 'upside potential' for CSL shares

A leading expert says CSL shares are now looking ‘cheap’.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Healthcare Shares

Telix shares crash 8% on US FDA blow

This high-flying stock has been hit with some bad news.

Read more »